USRE37838E1 - Composition for contraception - Google Patents
Composition for contraception Download PDFInfo
- Publication number
- USRE37838E1 USRE37838E1 US09/504,084 US50408400A USRE37838E US RE37838 E1 USRE37838 E1 US RE37838E1 US 50408400 A US50408400 A US 50408400A US RE37838 E USRE37838 E US RE37838E
- Authority
- US
- United States
- Prior art keywords
- placebo
- combination preparation
- days
- dosage units
- ethinylestradiol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates to the common use of estrogens and gestagens for the production of a combination preparation for oral contraception and a corresponding pack containing this combination preparation.
- Combination preparations for oral contraception are already known, for example, Femovan® [DE-PS 2 546 062] or Marvelon® [DE-OS 2 361 120]. These preparations consist of 21 active ingredient-containing (estrogen/gestagen) dosage units and 7 active ingredient-free coated tablets (sugar pills; placebos). The dose to be administered daily is uniformly high in each case (so-called single-phase preparations) and produces the desired contraceptive effect in the entire intake period and in the intake pause or during the intake of the placebos. In most preparations, a 7-day interruption of the intake of active ingredient-containing dosage units was considered necessary until quite recently to trigger a reliable withdrawal bleeding and thus to achieve a satisfactory cycle control.
- a combination preparation for substitution therapy and contraception for females before menopause is known from EP-A-0 253 607.
- This combination preparation contains an estrogen from the group
- a thus selected composition is to offset hormonal irregularities in the transition phase of premenopause and to help alleviate the symptoms caused by the hormonal changeover of the female organism in this phase.
- Such a composition simultaneously assures a premenopausal female the contraceptive protection still necessary at this age.
- the lowest estrogen dose contained in an oral contraceptive on the market at this time is 20 ⁇ g of ethinylestradiol, combined with 150 ⁇ g of desogestrel (Mercilon).
- desogestrel Mercilon
- the cycle control of this preparation is, as expected, somewhat poorer in comparison to preparations with a higher estrogen dose, the high acceptance rate of Mercilon indicates a small clinical relevance of this drawback.
- the observation, made identically in several studies, of a lesser ovarial suppression of the preparation containing 20 ⁇ g of ethinylestradiol represents a clinically important problem.
- the object of this invention is an improved single-phase combination preparation for a female of reproductive age, who is not yet in premenopause, containing an estrogen and gestagen in each individual dosage unit, with the lowest possible estrogen content in each individual dosage unit, but also with a low total hormone content per administration cycle.
- premenopause and “menopause” are used within the scope of this invention in the meaning of the conventional definition, see, for example, “The Controversial Climacteric,” P. A. of Keep et al., Ed., MTP press (1981), e.g., p. 9.
- the daily hormone dose is kept to a very low level here, while the usual 21-day intake is extended by two or three days.
- the remaining 5 or 4 days of a cycle are preferably bridged over by placebos, to avoid intake errors, or by 5 or 4 intake-free days.
- this relates to the use of a composition comprising an estrogen selected from
- this invention relates to a combination product for oral contraception, which comprises
- An especially preferred combination preparation according to this invention comprises 23 dosage units, each containing 20 ⁇ g of ethinylestradiol and 75 ⁇ g of gestodene and 5 sugar pills or other indications to show that no dosage unit or a sugar pill is administered during the last 5 days of the menstrual cycle.
- the ovarian suppression was measured based on the level of the endogenous 17 ⁇ -estradiol level and the size of follicular structures. The results show that the 17 ⁇ -estradiol levels with 23-day intake of the test preparation were significantly lower (p ⁇ 0.05) in comparison to the 21-day administration (FIG. 1 ).
- the combination preparation according to the invention thus achieves the effectiveness previously known for preparations with a daily content of 30 ⁇ g of ethinylestradiol, although the daily ethinylestradiol dose is 33% lower and also the total dose per cycle is 27% lower.
- the endogenous 17 ⁇ -estradiol levels are suppressed easily controllably in the case of the majority of the users of the 23-day preparation.
- Clinical symptoms such as breast tenseness, premenstrual syndrome and menstrual disorders; which can be attributed to increased and greatly fluctuating estrogen levels, are observed with the 23-day preparation with clearly lower frequency.
- an intake, extended by two (or three) days, of preparations containing 20 ⁇ g of ethinylestradiol in each daily dosage unit can produce the above-mentioned advantages, without the daily dose having to be raised to the previously largely used level of 30 ⁇ g of ethinylestradiol.
- an estrogen and gestagen for the use according to the invention or for a combination preparation according to the invention takes place completely analogously as it is already known for usual oral contraceptives with 21-day intake period of the active ingredients, such as, for example, Femovang (ethinylestradiol/gestodene) or Microgynon® (ethinylestradiol/levonorgestrel).
- active ingredients such as, for example, Femovang (ethinylestradiol/gestodene) or Microgynon® (ethinylestradiol/levonorgestrel).
- a pack containing a combination preparation according to the invention is also designed analogously to packs for already known oral contraceptives on the market with the variation that instead of the usual 21 dosage units containing the active components, now 23 or 24 such dosage units and 5 or 4 sugar pills are present or else contain other suitable indications that 5 or 4 days are to be bridged over until continuation of the intake of active ingredient-containing dosage units.
- EP-A 0 253 607 especially also to the statements there for determination of equivalent amounts of ethinylestradiol and 17 ⁇ -estradiol, on the one hand, and various gestagens, such as levonorgestrel, desogestrel, 3-ketodesogestrel and gestodene, on the other hand.
- FIG. 1 Area with the 17 ⁇ -estradiol level in groups of 30 females, who are treated with an oral contraceptive (75 ⁇ g of gestodene+20 ⁇ g of ethinylestradiol) in 21- or 23-day administration interval over three cycles.
- FIG. 2 Number of females in %, who showed follicular developments (>13 mm diameter) with 21- or 23-day treatment with an oral contraceptive (75 ⁇ g of gestodene+20 ⁇ g of ethinylestradiol).
Abstract
Description
Claims (15)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/504,084 USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US11/388,172 USRE43916E1 (en) | 1993-12-22 | 2006-03-24 | Composition for contraception |
US11/892,969 USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4344462A DE4344462C2 (en) | 1993-12-22 | 1993-12-22 | Composition for contraception |
DE4344462 | 1993-12-22 | ||
US08/268,996 US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US09/504,084 USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/268,996 Continuation US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 Reissue US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US11/892,969 Continuation USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US19375802A Continuation | 1993-12-22 | 2002-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE37838E1 true USRE37838E1 (en) | 2002-09-10 |
Family
ID=6506206
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/268,996 Expired - Lifetime US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 Ceased US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
US09/504,084 Expired - Lifetime USRE37838E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US09/503,952 Expired - Lifetime USRE37564E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US10/080,617 Expired - Lifetime USRE38253E1 (en) | 1993-12-22 | 2002-02-25 | Composition for contraception |
US11/388,172 Expired - Lifetime USRE43916E1 (en) | 1993-12-22 | 2006-03-24 | Composition for contraception |
US11/892,969 Expired - Lifetime USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/268,996 Expired - Lifetime US5583129A (en) | 1993-12-22 | 1994-06-30 | Composition for contraception |
US08/742,147 Ceased US5824667A (en) | 1993-12-22 | 1996-10-31 | Composition for contraception |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/503,952 Expired - Lifetime USRE37564E1 (en) | 1993-12-22 | 2000-02-15 | Composition for contraception |
US10/080,617 Expired - Lifetime USRE38253E1 (en) | 1993-12-22 | 2002-02-25 | Composition for contraception |
US11/388,172 Expired - Lifetime USRE43916E1 (en) | 1993-12-22 | 2006-03-24 | Composition for contraception |
US11/892,969 Expired - Lifetime USRE44159E1 (en) | 1993-12-22 | 2007-08-28 | Composition for contraception |
Country Status (21)
Country | Link |
---|---|
US (7) | US5583129A (en) |
EP (2) | EP0735883B1 (en) |
JP (4) | JPH09506888A (en) |
KR (1) | KR100369206B1 (en) |
CN (2) | CN1142185A (en) |
AT (1) | ATE344038T1 (en) |
CA (1) | CA2179728C (en) |
CZ (1) | CZ296387B6 (en) |
DE (2) | DE4344462C2 (en) |
DK (1) | DK0735883T3 (en) |
ES (1) | ES2276391T3 (en) |
HK (1) | HK1077743A1 (en) |
HU (1) | HUT74877A (en) |
NL (1) | NL300329I1 (en) |
NO (1) | NO316257B3 (en) |
NZ (1) | NZ278058A (en) |
PL (1) | PL187818B1 (en) |
PT (1) | PT735883E (en) |
RU (1) | RU2169567C2 (en) |
SK (1) | SK285965B6 (en) |
WO (1) | WO1995017194A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030139381A1 (en) * | 2001-12-05 | 2003-07-24 | Barr Laboratories, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US20040220152A1 (en) * | 2003-05-02 | 2004-11-04 | Ben-Maimon Carole S. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
US20050143359A1 (en) * | 2003-07-16 | 2005-06-30 | Bell Robert G. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
US20060058272A1 (en) * | 1999-08-31 | 2006-03-16 | Juergen Hilman | Pharmaceutical composition for use as a contraceptive |
WO2005105103A3 (en) * | 2004-04-30 | 2006-09-08 | Schering Ag | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
USRE39861E1 (en) | 1997-06-23 | 2007-09-25 | Duramed Pharmaceuticals, Inc. | Methods of extended use oral contraception |
US20080125402A1 (en) * | 2004-10-07 | 2008-05-29 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
US20090048218A1 (en) * | 2007-06-12 | 2009-02-19 | Joachim Kuhnke | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE |
US20090048217A1 (en) * | 2007-06-12 | 2009-02-19 | Joachim Kuhnke | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE |
US11376263B2 (en) | 2020-10-08 | 2022-07-05 | Fortress Biotech, Inc. | Cyproterone acetate compositions and uses thereof |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4344462C2 (en) | 1993-12-22 | 1996-02-01 | Schering Ag | Composition for contraception |
US6309843B1 (en) | 1994-10-25 | 2001-10-30 | The Curators Of The University Of Missouri | Glycoprotein for use in determining endometrial receptivity |
EP0792152B1 (en) * | 1994-11-22 | 2004-04-14 | Balance Pharmaceuticals, Inc. | Methods of contraception |
DE19513662A1 (en) * | 1995-04-08 | 1996-10-10 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
DE19540253C2 (en) * | 1995-10-28 | 1998-06-04 | Jenapharm Gmbh | Multi-phase preparation for contraception based on natural estrogens |
US5747480A (en) * | 1996-05-08 | 1998-05-05 | American Home Products Corporation | Oral contraceptive |
WO1997041872A1 (en) * | 1996-05-08 | 1997-11-13 | American Home Products Corporation | Oral contraceptive |
JP2000515888A (en) * | 1996-07-26 | 2000-11-28 | アメリカン・ホーム・プロダクツ・コーポレイション | Birth control pills |
US6479475B1 (en) | 1996-07-26 | 2002-11-12 | Wyeth | Oral contraceptive |
PT921804E (en) * | 1996-07-26 | 2004-01-30 | Wyeth Corp | BIPHASIC AND JOINT CONTRACEPTIVE METHOD ("KIT") COMPREHENDING A COMBINATION OF A PROGESTINE AND A STRTRENGTH |
AU3888697A (en) * | 1996-07-26 | 1998-02-20 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
US5888543A (en) * | 1996-07-26 | 1999-03-30 | American Home Products Corporation | Oral contraceptives |
US5858405A (en) * | 1996-07-26 | 1999-01-12 | American Home Products Corporation | Oral contraceptive |
US6451778B1 (en) | 1996-07-26 | 2002-09-17 | Wyeth | Oral contraceptive |
DE69729956T2 (en) * | 1996-07-26 | 2004-12-16 | Wyeth | ORAL, ONE-STEP CONCEPT PREVENTION METHOD AND COMBINATION PRODUCT CONTAINING THE STAGE AND ESTROGEN |
US6028064A (en) * | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
WO2001030355A1 (en) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Contraceptive medicine based on a progestational agent and an oestrogen and preparation method |
FR2754179B1 (en) * | 1996-10-08 | 1998-12-24 | Theramex | NOVEL HORMONONAL COMPOSITION AND ITS USE |
US6987101B1 (en) | 1996-12-20 | 2006-01-17 | Schering Aktiengesellschaft | Therapeutic gestagens for the treatment of premenstrual dysphoric disorder |
DE19654609A1 (en) * | 1996-12-20 | 1998-06-25 | Schering Ag | Therapeutic progestogens for the treatment of premenstrual dysphoric disorder |
ES2211580T3 (en) * | 1999-08-31 | 2004-07-16 | Schering Aktiengesellschaft | PHARMACEUTICAL COMBINATION OF ETHYLINESTRADIOL AND DROSPIRENONE FOR USE AS AN ANTI-CONCEPT. |
RU2269342C2 (en) * | 1999-08-31 | 2006-02-10 | Шеринг Акциенгезелльшафт | Pharmaceutical combination of ethynylestradiol and drospirenone for using as contraceptive |
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
US7025979B2 (en) * | 2000-02-15 | 2006-04-11 | Schering Ag | Male contraceptive formulation comprising norethisterone |
US20040176336A1 (en) * | 2000-03-21 | 2004-09-09 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
US20050113351A1 (en) * | 2000-03-21 | 2005-05-26 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
DE10045380A1 (en) * | 2000-09-14 | 2002-04-04 | Schering Ag | Contraception procedure and dosage form |
EP1216712A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
US20060142257A1 (en) * | 2001-01-19 | 2006-06-29 | Eberhard Nieschlag | Male contraceptive formulation comprising norethisterone |
JP2004521951A (en) * | 2001-07-13 | 2004-07-22 | シエーリング アクチエンゲゼルシャフト | Combination of drospirenone and estrogen sulfamate for HRT |
US6962908B2 (en) * | 2001-12-21 | 2005-11-08 | Warner Chilcott Company Inc. | Oral pharmaceutical products containing 17 β-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
WO2003090755A1 (en) * | 2002-04-26 | 2003-11-06 | Schering Aktiengesellschaft | Treatment of hypertension in women receiving hormone replacement therapy |
US7786101B2 (en) * | 2002-11-05 | 2010-08-31 | Bayer Schering Pharma Ag | Cardiovascular protection using anti-aldosteronic progestins |
GB0302572D0 (en) | 2003-02-05 | 2003-03-12 | Astrazeneca Ab | Method of treatment |
DE102004019743B4 (en) | 2004-04-20 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | Multiphase preparation for contraception based on natural estrogen |
DE102004026670A1 (en) | 2004-05-28 | 2005-12-15 | Grünenthal GmbH | Hormonal contraceptive containing a combination of ethinylestradiol and chlormadinone acetate |
US8501720B2 (en) * | 2004-07-30 | 2013-08-06 | Bayer Pharma AG | Method for treatment of dysmenorrhea |
EP1868593A2 (en) * | 2005-04-07 | 2007-12-26 | Hythiam, Inc. | Improved methods of and compositions for the prevention of anxiety, substance abuse, and dependence |
TW200744610A (en) * | 2005-06-21 | 2007-12-16 | Organon Nv | New regimens for controlled drug delivery devices for contraception |
TW200727920A (en) * | 2005-06-21 | 2007-08-01 | Organon Nv | New regimens for oral monophasic contraceptives |
US8153616B2 (en) * | 2005-10-17 | 2012-04-10 | Bayer Pharma Aktiengesellschaft | Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same |
EP1930010A1 (en) * | 2006-10-20 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Application of estradiol valerate or 17ß-estradiol in combination with dienogest for oral therapy to maintain and/or increase the female libido |
US20080242650A1 (en) * | 2007-03-26 | 2008-10-02 | Jean-Louis Thomas | Oral contraceptive regimen |
WO2009032874A2 (en) | 2007-09-06 | 2009-03-12 | The Coca-Cola Company | Systems and methods for providing portion control programming in a product forming dispenser |
BRPI0816482A2 (en) | 2007-09-06 | 2015-03-17 | Coca Cola Co | Methods for dispensing a product and an ingredient of the product, and dispensing apparatus |
EP2343963B1 (en) | 2008-10-08 | 2019-04-10 | Agile Therapeutics, Inc. | Transdermal delivery |
ES2795455T3 (en) | 2008-10-08 | 2020-11-23 | Agile Therapeutics Inc | Transdermal delivery |
WO2010042610A1 (en) | 2008-10-08 | 2010-04-15 | Agile Therapeutics, Inc. | Transdermal delivery |
CA2756222A1 (en) | 2009-03-27 | 2010-09-30 | Agile Therapeutics, Inc. | Transdermal delivery |
US9240028B2 (en) | 2011-08-26 | 2016-01-19 | Elwha Llc | Reporting system and method for ingestible product preparation system and method |
US10121218B2 (en) | 2012-06-12 | 2018-11-06 | Elwha Llc | Substrate structure injection treatment system and method for ingestible product system and method |
US20130054255A1 (en) * | 2011-08-26 | 2013-02-28 | Elwha LLC, a limited liability company of the State of Delaware | Controlled substance authorization and method for ingestible product preparation system and method |
US9037478B2 (en) | 2011-08-26 | 2015-05-19 | Elwha Llc | Substance allocation system and method for ingestible product preparation system and method |
US9997006B2 (en) | 2011-08-26 | 2018-06-12 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
US9785985B2 (en) | 2011-08-26 | 2017-10-10 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
US9947167B2 (en) | 2011-08-26 | 2018-04-17 | Elwha Llc | Treatment system and method for ingestible product dispensing system and method |
US8892249B2 (en) | 2011-08-26 | 2014-11-18 | Elwha Llc | Substance control system and method for dispensing systems |
US9922576B2 (en) | 2011-08-26 | 2018-03-20 | Elwha Llc | Ingestion intelligence acquisition system and method for ingestible material preparation system and method |
US20130331981A1 (en) | 2012-06-12 | 2013-12-12 | Elwha LLC, a limited liability company of the State of Delaware | Substrate Structure Deposition Treatment System And Method For Ingestible Product System And Method |
US9619958B2 (en) | 2012-06-12 | 2017-04-11 | Elwha Llc | Substrate structure duct treatment system and method for ingestible product system and method |
US10192037B2 (en) | 2011-08-26 | 2019-01-29 | Elwah LLC | Reporting system and method for ingestible product preparation system and method |
US9111256B2 (en) | 2011-08-26 | 2015-08-18 | Elwha Llc | Selection information system and method for ingestible product preparation system and method |
US8989895B2 (en) | 2011-08-26 | 2015-03-24 | Elwha, Llc | Substance control system and method for dispensing systems |
US10026336B2 (en) | 2011-08-26 | 2018-07-17 | Elwha Llc | Refuse intelligence acquisition system and method for ingestible product preparation system and method |
US20140122120A1 (en) * | 2012-10-30 | 2014-05-01 | Pacesetter, Inc. | Systems and methods for providing photo-based patient verification for use with implantable medical device programmers |
CN104546870B (en) * | 2015-01-27 | 2018-01-12 | 唐凡兰 | A kind of contraceptive |
RU2664437C2 (en) * | 2016-09-29 | 2018-08-17 | Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" | Means of prolonged action on the basis of proligestone to suppress estrus in small animals |
CN110548034A (en) * | 2019-07-12 | 2019-12-10 | 广州莎蔓生物科技有限公司 | Pregnancy-blocking medicine |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4129564A (en) | 1976-11-16 | 1978-12-12 | Schering, A.G. Patentabteilung | Spirolactones |
DE3023233A1 (en) | 1980-06-21 | 1982-01-07 | Berg & Co Gmbh, 4800 Bielefeld | Rotating lathe chuck actuating cylinder - has oil supplied via annular grooves in fixed housing contg. leak chambers returning oil to grooves |
EP0253607A1 (en) | 1986-07-15 | 1988-01-20 | American Home Products Corporation | Combination dosage form for premenopausal women |
EP0398460A2 (en) | 1989-05-16 | 1990-11-22 | Schering Aktiengesellschaft | Use of dihydrospirorenone as an anti-androgen |
EP0491438A1 (en) | 1990-12-17 | 1992-06-24 | Akzo Nobel N.V. | Contraceptive regimen |
EP0640343A1 (en) | 1993-07-01 | 1995-03-01 | Leiras Oy | Contraceptive for oral use containing oestradial valerate and cyproterone acetate |
DE4411585A1 (en) | 1994-03-30 | 1995-10-05 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
EP0491415B1 (en) | 1990-12-13 | 1996-04-03 | Akzo Nobel N.V. | Low estrogen oral contraceptives |
WO1998004268A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Oral contraceptive |
WO1998004265A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004246A2 (en) | 1996-07-26 | 1998-02-05 | American Home Prod | Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004267A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639600A (en) | 1969-08-28 | 1972-02-01 | Upjohn Co | Process of establishing cyclicity in a human female |
DE2310963A1 (en) | 1972-04-14 | 1974-09-05 | Schering Ag | METHOD OF CONTRACTION BY FOLLOWING STAGE COMBINATION PREPARATIONS |
US3969502A (en) | 1972-04-14 | 1976-07-13 | Schering Aktiengesellschaft | Method for contraception by the administration of sequential contraceptive preparations |
US3932635A (en) | 1972-04-24 | 1976-01-13 | Syntex Corporation | Novel cyclic progestogen-interrupted estrogen oral contraceptive regimens |
US3927046A (en) | 1972-12-09 | 1975-12-16 | Akzona Inc | Novel 11,11-alkylidene steroids |
DE2546062A1 (en) | 1975-10-10 | 1977-04-21 | Schering Ag | (17)-Alkynyl-(17)-hydroxy-(4,15)-oestradienones and derivs. - progestational agents inhibiting ovulation and implantation |
US4145416A (en) | 1976-06-23 | 1979-03-20 | Schering, A.G. | Novel agents and novel methods for treatment of climacteric disturbances |
DE3022337A1 (en) | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Compsns. for contraception or treatment of gynaecological disorders - contg. 6 beta, 7 beta; 15 delta, 16 beta-di:methylene-3-oxo-4-androstene-17(beta-1')-spiro-5'-per:hyd- ro-furan-2'-one |
US4826831A (en) | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
AU582540B2 (en) * | 1983-08-05 | 1989-04-06 | Pre Jay Holdings Ltd. | A method of hormonal treatment of perimenopausal, menopausal and post-menopausal disorders and multi-preparation pack therefor |
US4616006A (en) * | 1983-09-26 | 1986-10-07 | Ortho Pharmaceutical Corporation | Triphasic oral contraceptive |
DE3414508A1 (en) | 1984-04-13 | 1985-10-24 | Schering AG, 1000 Berlin und 4709 Bergkamen | MULTIPLE TRITLED STEROID-20.17-SPIROLACTONE AND THEIR USE AS TRACER SUBSTANCES |
US5010070A (en) | 1987-06-15 | 1991-04-23 | Warner-Lambert Company | Graduated estrogen contraceptive |
US5208225A (en) | 1986-02-27 | 1993-05-04 | Warner-Lambert Company | Compositions containing fixed combinations |
US5108995A (en) | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5422119A (en) | 1987-09-24 | 1995-06-06 | Jencap Research Ltd. | Transdermal hormone replacement therapy |
EP0309263B1 (en) * | 1987-09-24 | 1994-03-09 | Jencap Research Limited | Hormone composition and use |
US5256421A (en) | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
US5098714A (en) | 1989-11-16 | 1992-03-24 | Alza Corporation | Osmotic, oral dosage form for fertility control |
US5211952A (en) | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
DE4344462C2 (en) | 1993-12-22 | 1996-02-01 | Schering Ag | Composition for contraception |
US5552394A (en) * | 1994-07-22 | 1996-09-03 | The Medical College Of Hampton Roads | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
DE19510862A1 (en) | 1995-03-16 | 1996-09-19 | Schering Ag | Use of antiestrogens for male fertility control |
DE69729956T2 (en) | 1996-07-26 | 2004-12-16 | Wyeth | ORAL, ONE-STEP CONCEPT PREVENTION METHOD AND COMBINATION PRODUCT CONTAINING THE STAGE AND ESTROGEN |
FR2754179B1 (en) | 1996-10-08 | 1998-12-24 | Theramex | NOVEL HORMONONAL COMPOSITION AND ITS USE |
SI1462107T1 (en) | 2003-03-28 | 2009-02-28 | Pantarhei Bioscience Bv | Method of female contraception and kit for use in such method |
-
1993
- 1993-12-22 DE DE4344462A patent/DE4344462C2/en not_active Expired - Lifetime
-
1994
- 1994-06-30 US US08/268,996 patent/US5583129A/en not_active Expired - Lifetime
- 1994-12-22 DK DK95905574T patent/DK0735883T3/en active
- 1994-12-22 CN CN94194888A patent/CN1142185A/en active Pending
- 1994-12-22 ES ES95905574T patent/ES2276391T3/en not_active Expired - Lifetime
- 1994-12-22 PT PT95905574T patent/PT735883E/en unknown
- 1994-12-22 EP EP95905574A patent/EP0735883B1/en not_active Revoked
- 1994-12-22 WO PCT/EP1994/004274 patent/WO1995017194A1/en active IP Right Grant
- 1994-12-22 NZ NZ278058A patent/NZ278058A/en not_active IP Right Cessation
- 1994-12-22 RU RU96115196/14A patent/RU2169567C2/en active
- 1994-12-22 AT AT95905574T patent/ATE344038T1/en active
- 1994-12-22 CN CNB2004100590293A patent/CN100377713C/en not_active Ceased
- 1994-12-22 SK SK831-96A patent/SK285965B6/en not_active IP Right Cessation
- 1994-12-22 CZ CZ0186196A patent/CZ296387B6/en not_active IP Right Cessation
- 1994-12-22 PL PL94315168A patent/PL187818B1/en unknown
- 1994-12-22 KR KR1019960703408A patent/KR100369206B1/en not_active IP Right Cessation
- 1994-12-22 EP EP06076732A patent/EP1726308A3/en not_active Ceased
- 1994-12-22 CA CA002179728A patent/CA2179728C/en not_active Expired - Lifetime
- 1994-12-22 DE DE59410444T patent/DE59410444D1/en not_active Expired - Lifetime
- 1994-12-22 HU HU9601750A patent/HUT74877A/en not_active Application Discontinuation
- 1994-12-22 JP JP7517199A patent/JPH09506888A/en not_active Withdrawn
-
1996
- 1996-06-24 NO NO19962676A patent/NO316257B3/en not_active IP Right Cessation
- 1996-10-31 US US08/742,147 patent/US5824667A/en not_active Ceased
-
2000
- 2000-02-15 US US09/504,084 patent/USRE37838E1/en not_active Expired - Lifetime
- 2000-02-15 US US09/503,952 patent/USRE37564E1/en not_active Expired - Lifetime
-
2002
- 2002-02-25 US US10/080,617 patent/USRE38253E1/en not_active Expired - Lifetime
-
2005
- 2005-11-03 HK HK05109807.9A patent/HK1077743A1/en not_active IP Right Cessation
-
2006
- 2006-01-04 JP JP2006000148A patent/JP2006096775A/en not_active Withdrawn
- 2006-03-24 US US11/388,172 patent/USRE43916E1/en not_active Expired - Lifetime
-
2007
- 2007-08-28 US US11/892,969 patent/USRE44159E1/en not_active Expired - Lifetime
-
2008
- 2008-01-07 NL NL300329C patent/NL300329I1/en unknown
-
2010
- 2010-08-06 JP JP2010177241A patent/JP2010248270A/en not_active Withdrawn
-
2013
- 2013-03-13 JP JP2013049933A patent/JP2013139464A/en active Pending
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4129564A (en) | 1976-11-16 | 1978-12-12 | Schering, A.G. Patentabteilung | Spirolactones |
DE3023233A1 (en) | 1980-06-21 | 1982-01-07 | Berg & Co Gmbh, 4800 Bielefeld | Rotating lathe chuck actuating cylinder - has oil supplied via annular grooves in fixed housing contg. leak chambers returning oil to grooves |
EP0253607A1 (en) | 1986-07-15 | 1988-01-20 | American Home Products Corporation | Combination dosage form for premenopausal women |
US5569652A (en) | 1989-05-16 | 1996-10-29 | Schering Aktiengesellschaft | Dihydrospirorenone as an antiandrogen |
EP0398460A2 (en) | 1989-05-16 | 1990-11-22 | Schering Aktiengesellschaft | Use of dihydrospirorenone as an anti-androgen |
EP0491415B1 (en) | 1990-12-13 | 1996-04-03 | Akzo Nobel N.V. | Low estrogen oral contraceptives |
EP0491438A1 (en) | 1990-12-17 | 1992-06-24 | Akzo Nobel N.V. | Contraceptive regimen |
EP0640343A1 (en) | 1993-07-01 | 1995-03-01 | Leiras Oy | Contraceptive for oral use containing oestradial valerate and cyproterone acetate |
DE4411585A1 (en) | 1994-03-30 | 1995-10-05 | Schering Ag | Combined pharmaceutical preparation for hormonal contraception |
WO1995026730A1 (en) | 1994-03-30 | 1995-10-12 | Schering Aktiengesellschaft | Combined hormonal contraception pharmaceutical preparation |
US5756490A (en) | 1994-03-30 | 1998-05-26 | Schering Aktiengesellschaft | Pharmaceutical combination preparation for hormonal contraception |
WO1998004268A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Oral contraceptive |
WO1998004265A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Biphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004246A2 (en) | 1996-07-26 | 1998-02-05 | American Home Prod | Triphasic contraceptive method and kit comprising a combination of a progestin and estrogen |
WO1998004267A1 (en) | 1996-07-26 | 1998-02-05 | American Home Products Corporation | Progestin/estrogen oral contraceptive |
Non-Patent Citations (32)
Title |
---|
A.R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, "Multicenter Clinical Trial on the new Oral Contraceptive Containing 20 mug Ethinylestradiol", Chapter 1, pp. 747-756, (1990). |
A.R. Genazzani, et al. (Ed), Progress in Gynecology and Obstetrics, "Multicenter Clinical Trial on the new Oral Contraceptive Containing 20 μg Ethinylestradiol", Chapter 1, pp. 747-756, (1990). |
Calaf-Alsina et al., "Obstet Gynecol", 69, pp. 255-258, (Abstract only) (1987). |
Düsterberg et al., "Acta Obstet Gynecol Scand. Suppl.", 88, pp. 27-31, (1979). |
Elstein et al., Zentralblatt fur Gynäkologie, 117, pp. 559-565, (1995). |
Filshie and Guillebaud, eds., "Contraception: Science and Practice", 69-93 (1989). |
Foidart et al., "Int'l J. Gynecol & Obstet", 46, Suppl. 3, p. 11, (1994). |
G.B. Melis, et al., Contraception, "A Comparative Study on the Effects of a Monophasic Pill Containing Desogestrel Plus 20 mug Ethinylestradiol, a Triphasic Combination Levonorgestrel and a Monophasic Combination Containing gestrodene on Coagulatory Factors", vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract]. |
G.B. Melis, et al., Contraception, "A Comparative Study on the Effects of a Monophasic Pill Containing Desogestrel Plus 20 μg Ethinylestradiol, a Triphasic Combination Levonorgestrel and a Monophasic Combination Containing gestrodene on Coagulatory Factors", vol. 43, No. 1, pp. 23-30 (Jan. 1991), [including abstract]. |
German Pharmacopeia, 9th Edition, 1986-English Translation. |
German Pharmacopeia, 9th Edition, 1986—English Translation. |
Holdaway et al., "Acta Endocrinol", 109, 522-529, (Abstract only) (1985). |
Huernpel et al., Contraception, 16, pp. 199-216 (Abstract only), (1977). |
J. Guillebaud, Br. J Family Planning, 12 (Suppl.), 35-43 (1987). |
Jandrain et al., "Am J. Obstet Gynecol", 163, pp. 378-381, (1990). |
Klebe et al. "Arch Gynecol", 234, pp. 113-120, (Abstract only) (1985). |
Kuhl et al., "Contraception", pp. 467-482, (1985). |
Kuhnz et al., "Contraception", 48, pp. 557-575, (1993). |
Larsson-Cohn et al., "Acta Obstet Gynecol Scand", 65, pp. 125-128, (Abstract only) (1986). |
Leis et al., "Geburtshilfe Frauenheilkd", 39, pp. 54-57 (Abstract only), (1979). |
M. Elstein, "Advaces in Contraception", 12, pp. 155-156, (1996). |
Oelkers et al., "Advances in Constraception", 7, Suppl. 3, pp. 195-206 (1991). |
Parke Davis package insert for Loestrin, Jun., 1993. |
PCT Search Report dated May 12, 1995.* * |
Porcile et al., "Fertiliry and Sterility", 55, pp. 877-881, (Abstract only) (1991). |
Scheen et al., "Fertility and Sterility", 59, pp. 797-802, (Abstract only) (1993). |
Schillinger et al., "Arzneim.-Forsch.", 26, pp. 2242-2245, (Abstract only), (1976). |
Spona et al., "Gynecol Obstet Invest", 23, pp. 184-193, (1987). |
Van Keep et al., eds. "The Controvresial Climactoric", MTP Press Limited, 9-18 (1981). |
W. Oelkers et al., "Acta Endocrinologica", Suppl. 4, p. 71, #97, (1992) (Abstract Only). |
W. Oelkers et al., "Journal of Clinical Endocrinology and Metabolism", 80, pp. 1816-1821. |
W. Oelkers et al., "Journal of Clinical Endocrinology and Metabolism", p. 73, pp. 837-842, (1991). |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE39861E1 (en) | 1997-06-23 | 2007-09-25 | Duramed Pharmaceuticals, Inc. | Methods of extended use oral contraception |
US20060058272A1 (en) * | 1999-08-31 | 2006-03-16 | Juergen Hilman | Pharmaceutical composition for use as a contraceptive |
US20030139381A1 (en) * | 2001-12-05 | 2003-07-24 | Barr Laboratories, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US8680084B2 (en) | 2001-12-05 | 2014-03-25 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US7320969B2 (en) | 2001-12-05 | 2008-01-22 | Duramed Pharmaceuticals, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US8338396B2 (en) | 2001-12-05 | 2012-12-25 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US7858605B2 (en) | 2001-12-05 | 2010-12-28 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US7615545B2 (en) | 2001-12-05 | 2009-11-10 | Duramed Pharmaceuticals, Inc. | Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology |
US20100298279A1 (en) * | 2001-12-05 | 2010-11-25 | Bell Robert G | Oral Contraceptives to Prevent Pregnancy and Diminish Premenstrual Symptomatology |
US20040220152A1 (en) * | 2003-05-02 | 2004-11-04 | Ben-Maimon Carole S. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
US7772219B2 (en) | 2003-05-02 | 2010-08-10 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing extended cycle contraceptive regimens |
US20050143359A1 (en) * | 2003-07-16 | 2005-06-30 | Bell Robert G. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
US7855190B2 (en) | 2003-07-16 | 2010-12-21 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
US20110124611A1 (en) * | 2003-07-16 | 2011-05-26 | Teva Women's Health, Inc. | Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration |
JP2007535519A (en) * | 2004-04-30 | 2007-12-06 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | Management of broken bleeding in extended hormonal contraception |
AU2005237255B2 (en) * | 2004-04-30 | 2011-07-07 | Bayer Intellectual Property Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
EA016625B1 (en) * | 2004-04-30 | 2012-06-29 | Байер Фарма Акциенгезельшафт | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
WO2005105103A3 (en) * | 2004-04-30 | 2006-09-08 | Schering Ag | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
EA031227B1 (en) * | 2004-04-30 | 2018-12-28 | Байер Интеллекчуал Проперти Гмбх | METHOD OF ORAL CONTRACEPTION IN WOMEN, METHOD FOR PREVENTING NON-DESIRABLE BLEEDING DURING ORAL CONTRACEPTION IN WOMEN AND PHARMACEUTICAL KIT FOR APPLICATION IN THESE METHODS |
US20080125402A1 (en) * | 2004-10-07 | 2008-05-29 | Duramed Pharmaceuticals, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
US8415332B2 (en) | 2004-10-07 | 2013-04-09 | TEVA Woman's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
US8450299B2 (en) | 2004-10-07 | 2013-05-28 | Teva Womans's Health, Inc. | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens |
US20090048217A1 (en) * | 2007-06-12 | 2009-02-19 | Joachim Kuhnke | 17Beta-CYANO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE |
US20090048218A1 (en) * | 2007-06-12 | 2009-02-19 | Joachim Kuhnke | 17Beta-CYANO-18A-HOMO-19-NOR-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE |
US8207150B2 (en) * | 2007-06-12 | 2012-06-26 | Bayer Pharma AG | 17β-cyano-19-nor-androst-4-ene derivative, its use and medicaments comprising the derivative |
US11376263B2 (en) | 2020-10-08 | 2022-07-05 | Fortress Biotech, Inc. | Cyproterone acetate compositions and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE37838E1 (en) | Composition for contraception | |
US6312722B1 (en) | Pharmaceutical combined preparation, kit and method for hormonal contraception | |
US5756490A (en) | Pharmaceutical combination preparation for hormonal contraception | |
US5552394A (en) | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy | |
US5980940A (en) | Pharmaceutical combination preparation for hormonal contraception | |
AU722362B2 (en) | Pharmaceutical combination preparation for hormonal contraception | |
MXPA96004440A (en) | Preparation of a pharmaceutical combination for oven contraception | |
MXPA98000026A (en) | Combined pharmaceutical preparation, equipment and method for hormo contraception |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCHERING AKTIENGESELLSCHAFT, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SPONA, JURGEN;DUSTERBERG, BERND;LUDICKE, FRANK;REEL/FRAME:011043/0146;SIGNING DATES FROM 20000516 TO 20000605 |
|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REIN | Reinstatement after maintenance fee payment confirmed | ||
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES FILED (ORIGINAL EVENT CODE: PMFP); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PMFG); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
SULP | Surcharge for late payment | ||
PRDP | Patent reinstated due to the acceptance of a late maintenance fee |
Effective date: 20020910 |
|
AS | Assignment |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020156/0001 Effective date: 20061229 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FPAY | Fee payment |
Year of fee payment: 12 |